Obesity-related asthma is a growing clinical challenge, characterized by poor response to conventional asthma therapies and more severe disease. Obesity not only increases the risk of developing asthma but also contributes to altered lung function and airway inflammation. Although weight loss has shown significant improvements in asthma symptoms, it remains unfeasible for many patients, highlighting the urgency for better understanding of the underlying mechanisms and new treatment approaches.
Recent studies have explored the role of non-type 2 inflammation, metabolic syndrome, and small airway impairment in obesity-related asthma. Emerging therapies under investigation include biologics, structured weight reduction programs, and novel anti-obesity medications targeting metabolic dysfunction. While weight loss remains the most effective strategy, the development of new pharmacologic treatments may provide more accessible and tailored options for this prevalent asthma phenotype.
Reference: Witte A, Türk Y, Braunstahl GJ. Obesity-related asthma: new insights leading to a different approach. Curr Opin Pulm Med. 2024 May 1;30(3):294-302. doi: 10.1097/MCP.0000000000001073. Epub 2024 Mar 4. PMID: 38441436.
